GlassScriptPrepare for your visit
Ashwin K Ravichandran
Advanced Heart Failure and Transplant Cardiology · Indianapolis, IN · NPI 1407012776
One page to bring to your appointment. Every figure is as reported to CMS by drug and device makers. Payments are legal and often routine; this is context for a conversation, not a verdict.
What was reported
$284,241.20
in general payments reported to CMS, 2019-2025 · $40K in 2025
The $40K reported for 2025 was more than what 90% of Advanced Heart Failure and Transplant Cardiology providers received nationally (typical 2025 total: $1,046).
Who reported paying
General payments only, top 6 by amount.
- Actelion Pharmaceuticals US, INC. $106,057.08
- United Therapeutics Corporation $57,751.36
- Abbott Laboratories $41,349.21
- Bayer Healthcare Pharmaceuticals INC. $22,155.90
- Cvrx, INC. $15,228.35
- Merck Sharp & Dohme LLC $13,366.34
Drugs and devices associated with these payments
Opsumit Uptravi Barostim Neo System Winrevair Thoratec Heartmate 3 Lvas Implant Kit Cardiomems Remodulin Optimizer Camzyos Impella Mitraclip Tyvaso
Association is not allocation: a product listed here means a payment was associated with it, not that money was paid to promote it. Detail covers 2023-2025.
Questions you might ask
- I saw Ashwin Ravichandran listed in the CMS Open Payments database. Can you tell me about your work with those companies?
- Is there a generic or alternative to this medication, and would it work as well for me?
- What made you choose this particular treatment for my situation?
These are normal questions. A good clinician will welcome them.
Notes
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.
GlassScript is independent and not affiliated with CMS or any government agency. glasscript.com/doctor/108258/ashwin-k-ravichandran